Fostering Hope Through New Therapies
About Us
BIOSIRIUS Ltd stands at the forefront of biotechnology innovation, transforming valuable intellectual property into breakthrough therapeutic solutions. Founded in 2021 and headquartered in Dorset, UK, we are a specialised pharmaceutical IP licensing company dedicated to bridging the critical gap between groundbreaking scientific discovery and patient access to life-changing treatments.
​
Our Journey to Innovation
Biosirius Ltd is reshaping the approach to treating severe viral pneumonia by focusing on Interleukin-18 (IL-18). With patents in over 25 European countries and a robust clinical study published in February 2023, we aim to enhance patient outcomes through targeted therapies and advanced research.
​
Read More
Our Message
Our approach has focussed on identifying free Interleukin-18 (IL-18) as a major driver of morbidity and mortality in severe viral pneumonia.
​
Our patent coverage in more than 25 European Countries on IL-18 binding in severe viral pneumonia, makes us the gate-keepers of this new treatment method in a disease with a 30 - 50% mortality rate, with millions of sufferers worldwide, in a multi-billion dollar interleukin-inhibition market.
​